Patents by Inventor Jianhe Chen
Jianhe Chen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230399394Abstract: The present invention relates to an antibody binding to human IL-33 or an antigen-binding fragment thereof, which can bind to the human IL-33 with a high affinity and block the binding of ST2 to IL-33, can be used in the preparation of a drug for treating diseases with a high IL-33 expression (such as asthma, atopic/allergic dermatitis, chronic rhino sinusitis and chronic obstructive pulmonary diseases (COPD)), and has good clinical application prospects.Type: ApplicationFiled: September 26, 2021Publication date: December 14, 2023Applicant: SUNSHINE GUOJIAN PHARMACEUTICAL (SHANGHAI) CO., LTD.Inventors: Wei Guo, Xuesai Zhang, Huiting Xu, Qingrou Li, Le Zhao, Jianhe Chen, Haomin Huang, Zhenping Zhu
-
Publication number: 20230348880Abstract: A soluble ACF and a truncated form thereof, a fusion protein thereof and preparation methods therefor. A soluble ACEI and a truncated form thereof, as well as a use of the fusion protein in the preparation of a drug for an ACEI-related disease.Type: ApplicationFiled: February 27, 2021Publication date: November 2, 2023Applicant: National Institute of Biological Sciences, BeijingInventors: Wenhui Li, Yonghe Qi, Jianhe Chen, Jianhua Sui, Juan Liu, Fengfeng Mao, Ximing Liu
-
Publication number: 20230322943Abstract: An antibody or an antigen-binding fragment thereof that binds to human CD38. The antibody or the antigen-binding fragment thereof can effectively bind to human CD38 and is applied to preparing a drug for treating diseases having strong CD38 expression (such as multiple myeloma), thereby having good prospects in clinical application.Type: ApplicationFiled: August 11, 2021Publication date: October 12, 2023Applicant: SUNSHINE GUOJIAN PHARMACEUTICAL (SHANGHAI) CO., LTD.Inventors: Wei Guo, Jie Zhao, Le Zhao, Qingcheng Liu, Jianhe Chen, Haomin Huang, Zhenping Zhu
-
Publication number: 20230058721Abstract: The present invention relates to multispecific procoagulant antibodies capable of binding to coagulation Factor IX (FIX) and/or the activated form thereof Factor IXa (FIXa), and Factor X (FX) and/or the activated form thereof Factor Xa (FXa) and promoting FX activation by FIXa, antibodies binding their epitopes or parts thereof and methods and composition for treating subjects suffering from a coagulopathy such as haemophilia A as well as kits, methods of manufacture and methods of use.Type: ApplicationFiled: November 10, 2021Publication date: February 23, 2023Inventors: Karina Thorn, Bjarne Gram Hansen, Laust Bruun Johnsen, Mikkel Nors Harndahl, Zhiru Yang, Henrik Oestergaard, Per J. Greisen, Eva Johansson, Morten Groenbech Rasch, Jianhe Chen, Anders Svensson, Haisun Zhu, Rong Zhou, Prafull S. Gandhi
-
Patent number: 11254746Abstract: An anti-human PD-1 monoclonal antibody, and a preparation method therefor and an application thereof. The anti-human PD-1 monoclonal antibody has good bioactivity, can effectively bind with an extracellular region of a human PD-1 protein receptor, and can effectively seal PD-1 protein at protein level and cellular level and block the binding of the PD-1 protein with a ligand PD-L1, thereby effectively enhancing immunity. The monoclonal antibody can be applied independently or jointly with other antitumor drugs to tumor immunotherapy and the diagnosis and screening of patients with PD-L1 positive tumors; and the monoclonal antibody has a promising prospect in the preparation of drugs for treating tumors, resisting autoimmune diseases and the like.Type: GrantFiled: January 22, 2018Date of Patent: February 22, 2022Assignee: SUNSHINE GUOJIAN PHARMACEUTICAL (SHANGHAI) CO., LTInventors: Jie Zhao, Honghai Gao, Jinlin Guo, Wei Dang, Lingqiao Zhu, Chenghai Zhang, Le Zhao, Jianhe Chen, Haomin Huang, Zhenping Zhu
-
Patent number: 11220554Abstract: The present invention relates to multispecific procoagulant antibodies capable of binding to coagulation Factor IX (FIX) and/or the activated form thereof Factor IXa (FIXa), and Factor X (FX) and/or the activated form thereof Factor Xa (FXa) and promoting FX activation by FIXa, antibodies binding their epitopes or parts thereof and methods and composition for treating subjects suffering from a coagulopathy such as haemophilia A as well as kits, methods of manufacture and methods of use.Type: GrantFiled: January 29, 2021Date of Patent: January 11, 2022Assignee: Novo Nordisk A/SInventors: Karina Thorn, Bjarne Gram Hansen, Laust Bruun Johnsen, Mikkel Nors Harndahl, Zhiru Yang, Henrik Oestergaard, Per J. Greisen, Eva Johansson, Morten Groenbech Rasch, Jianhe Chen, Anders Svensson, Haisun Zhu, Rong Zhou, Prafull S. Gandhi
-
Publication number: 20210388114Abstract: The present invention relates to improved procoagulant antibodies including bispecific antibodies capable of binding to coagulation Factor IX (FIX) or the activated form thereof Factor IXa (FIXa) and optionally Factor X (FX) and the activated form thereof Factor Xa (FXa) and promoting FX activation by FIXa, antibodies binding their epitopes and methods and composition for treating subjects suffering from a coagulopathy such as haemophilia A.Type: ApplicationFiled: February 1, 2018Publication date: December 16, 2021Inventors: Karina Thorn, Bjarne Gram Hansen, Laust Bruun Johnsen, Mikkel Nors Harndahl, Zhiru Yang, Henrik Oestergaard, Per J. Greisen, Eva Johansson, Morten Groenbech Rasch, Jianhe Chen, Anders Svensson, Haisun Zhu, Rong Zhou, Prafull S. Gandhi
-
Publication number: 20210309759Abstract: Provided is an antibody binding to human HER2 or an antigen-binding fragment thereof capable of specifically binding to human HER2. Compared with Perjeta, the combination of the antibody or an antigen-binding fragment thereof and Herceptin has improved biological activity in inhibiting the proliferation of tumor cells overexpressing HER2. The antibody or an antigen-binding fragment thereof has an antigen-binding epitope different from known antibodies binding to human HER2, can be used to prepare a drug for treating a disease related to HER2 overexpression, such as cancer, and has good prospects for clinical application.Type: ApplicationFiled: August 1, 2019Publication date: October 7, 2021Inventors: Jianhe CHEN, Xuesai ZHANG, Le ZHAO, Fei XU, Qingrou LI, Haomin HUANG, Zhenping ZHU
-
Publication number: 20210238306Abstract: The present invention relates to multispecific procoagulant antibodies capable of binding to coagulation Factor IX (FIX) and/or the activated form thereof Factor IXa (FIXa), and Factor X (FX) and/or the activated form thereof Factor Xa (FXa) and promoting FX activation by FIXa, antibodies binding their epitopes or parts thereof and methods and composition for treating subjects suffering from a coagulopathy such as haemophilia A as well as kits, methods of manufacture and methods of use.Type: ApplicationFiled: January 29, 2021Publication date: August 5, 2021Inventors: Karina Thorn, Bjarne Gram Hansen, Laust Bruun Johnsen, Mikkel Nors Harndahl, Zhiru Yang, Henrik Oestergaard, Per J. Greisen, Eva Johansson, Morten Groenbech Rasch, Jianhe Chen, Anders Svensson, Haisun Zhu, Rong Zhou
-
Publication number: 20200407409Abstract: The invention relates to compounds derived from the EGF(A) domain of LDL-R, in particular compounds comprising a peptide analogue of the wild-type EGF(A) (LDL-R(293-332)) sequence and at least one substituent comprising at least one fatty acid group. The invention also relates to a pharmaceutical composition thereof and use a medicament. The novel EGF(A) compounds of the invention are useful as treatment e.g. in the field of cholesterol lowering, dyslipidaemia and cardiovascular disease.Type: ApplicationFiled: September 17, 2020Publication date: December 31, 2020Inventors: Jianhe Chen, Jesper F. Lau, Janos Tibor Kodra, Birgit Wieczorek, Lars Linderoth, Henning Thoegersen, Salka Elboel Rasmussen, Patrick William Garibay
-
Publication number: 20200377597Abstract: An anti-human PD-1 monoclonal antibody, and a preparation method therefor and an application thereof. The anti-human PD-1 monoclonal antibody has good bioactivity, can effectively bind with an extracellular region of a human PD-1 protein receptor, and can effectively seal PD-1 protein at protein level and cellular level and block the binding of the PD-1 protein with a ligand PD-L1, thereby effectively enhancing immunity. The monoclonal antibody can be applied independently or jointly with other antitumor drugs to tumor immunotherapy and the diagnosis and screening of patients with PD-L1 positive tumors; and the monoclonal antibody has a promising prospect in the preparation of drugs for treating tumors, resisting autoimmune diseases and the like.Type: ApplicationFiled: January 22, 2018Publication date: December 3, 2020Inventors: Jie Zhao, Honghai Gao, Jinlin Guo, Wei Dang, Lingqiao Zhu, Chenghai Zhang, Le Zhao, Jianhe Chen, Haomin Huang, Zhenping Zhu
-
Patent number: 10822385Abstract: The invention relates to compounds derived from the EGF(A) domain of LDL-R, in particular compounds comprising a peptide analogue of the wild-type EGF(A) (LDL-R(293-332)) sequence and at least one substituent comprising at least one fatty acid group. The invention also relates to a pharmaceutical composition thereof and use a medicament. The novel EGF(A) compounds of the invention are useful as treatment e.g. in the field of cholesterol lowering, dyslipidaemia and cardiovascular disease.Type: GrantFiled: January 13, 2017Date of Patent: November 3, 2020Assignee: Novo Nordisk A/SInventors: Jianhe Chen, Jesper F. Lau, Janos Tibor Kodra, Birgit Wieczorek, Lars Linderoth, Henning Thoegersen, Salka Elboel Rasmussen, Patrick William Garibay
-
Publication number: 20190016768Abstract: The invention relates to compounds derived from the EGF(A) domain of LDL-R, in particular compounds comprising a peptide analogue of the wild-type EGF(A) (LDL-R(293-332)) sequence and at least one substituent comprising at least one fatty acid group. The invention also relates to a pharmaceutical composition thereof and use a medicament. The novel EGF(A) compounds of the invention are useful as treatment e.g. in the field of cholesterol lowering, dyslipidaemia and cardiovascular disease.Type: ApplicationFiled: January 13, 2017Publication date: January 17, 2019Inventors: Jianhe Chen, Jesper F. Lau, Janos Tibor Kodra, Birgit Wieczorek, Lars Linderoth, Henning Thoegersen, Salka Elboel Rasmussen, Patrick William Garibay
-
Patent number: 9523074Abstract: Provided are a sub-totipotent stem cell product and epigenetic modification label thereof, a method for inducing the generation of the sub-totipotent stem cell product and identification for the epigenetic modification label of the differentiation potential of stem cells. Also provided is a use of histone modification states of sub-totipotent genes and/or differentiation related genes to predict the epigenetic modification label of the differentiation potentials of stem cells.Type: GrantFiled: December 2, 2011Date of Patent: December 20, 2016Assignee: NEWISH TECHNOLOGY (BEIJING) CO., LTD.Inventors: Chunhua Zhao, Jing Li, Hongling Li, Jianhe Chen, Qin Han, Kanghua Li, Jing Wang
-
Patent number: 9422368Abstract: The present invention relates to agents that are non-competitive antagonists of the CD94/NKG2A receptor such as certain anti-NKG2A antibodies, in particular humanized versions of murine anti-NKG2A antibody Z199, as well as methods of producing and using such agents and antibodies.Type: GrantFiled: August 1, 2014Date of Patent: August 23, 2016Assignee: NOVO NORDISK A/SInventors: Petrus Johannes Louis Spee, Jianhe Chen, Soren Berg Padkjaer, Jing Su, Jinchao Zhang, Jiujiu Yu
-
Patent number: 9211342Abstract: The present invention relates to growth hormone (GH) compounds having additional disulphide bridges and at least one additional single point mutation making the compounds resistant to proteolytic degradation.Type: GrantFiled: January 24, 2011Date of Patent: December 15, 2015Assignee: NOVO NORDISK HEALTHCARE AGInventors: Helle Demuth, Christine Brunn Schioedt, Leif Noerskov-Lauritsen, Jianhe Chen, Peter Thygesen
-
Publication number: 20140341896Abstract: The present invention relates to agents that are non-competitive antagonists of the CD94/NKG2A receptor such as certain anti-NKG2A antibodies, in particular humanized versions of murine anti-NKG2A antibody Z199, as well as methods of producing and using such agents and antibodies.Type: ApplicationFiled: August 1, 2014Publication date: November 20, 2014Inventors: PETRUS JOHANNES LOUIS SPEE, JIANHE CHEN, SOREN BERG PADKJAER, JING SU, JINCHAO ZHANG, JIUJIU YU
-
Publication number: 20140287930Abstract: Provided are a sub-totipotent stem cell product and epigenetic modification label thereof, a method for inducing the generation of the sub-totipotent stem cell product and identification for the epigenetic modification label of the differentiation potential of stem cells. Also provided is a use of histone modification states of sub-totipotent genes and/or differentiation related genes to predict the epigenetic modification label of the differentiation potentials of stem cells.Type: ApplicationFiled: December 2, 2011Publication date: September 25, 2014Applicant: Beijing Jingyuan Yangeng Biotechnologies Co., Ltd.Inventors: Chunhua Zhao, Jing Li, Hongling Li, Jianhe Chen, Qin Han, Kanghua Li, Jing Wang
-
Patent number: 8796427Abstract: The present invention relates to agents that are non-competitive antagonists of the CD94/NKG2A receptor such as certain anti-NKG2A antibodies, in particular humanized versions of murine anti-NKG2A antibody Z199, as well as methods of producing and using such agents and antibodies.Type: GrantFiled: January 23, 2009Date of Patent: August 5, 2014Assignee: Novo Nordisk A/SInventors: Petrus Johannes Louis Spee, Jianhe Chen, Søren Berg Padkjær, Jing Su, Jinchao Zhang, Jiujiu Yu
-
Publication number: 20130040883Abstract: The present invention relates to growth hormone (GH) compounds having additional disulphide bridges and at least one additional single point mutation making the compounds resistant to proteolytic degradation.Type: ApplicationFiled: January 24, 2011Publication date: February 14, 2013Applicant: Novo Nordisk HealthCare AGInventors: Helle Demuth, Christine Brunn Schioedt, Leif Noerskov-Lauritsen, Jianhe Chen, Peter Thygesen